--- title: "Weekly Recap | Eli Lilly +1.31%, closing in on record highs" type: "News" locale: "en" url: "https://longbridge.com/en/news/302952272.md" description: "Eli Lilly (LLY) rose 1.31% this week to close at $1,273.46, while the S&P 500 fell 0.47%, leaving the stock about 1.78 percentage points ahead of the benchmark. The weekly range was 6.6%, with an up-and-down pattern: Monday opened at $1,243.39 and slipped to a low of $1,239.10; Tuesday gapped higher, hit $1,311.75 intraday, and closed at $1,283.66; Thursday reached a weekly high of $1,321.21; Friday climbed to $1,307.92 before pulling back to end at $1,273.46." datetime: "2026-10-24T06:34:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302952272.md) - [en](https://longbridge.com/en/news/302952272.md) - [zh-HK](https://longbridge.com/zh-HK/news/302952272.md) generator: "portal-rs" --- # Weekly Recap | Eli Lilly +1.31%, closing in on record highs ## The Week Eli Lilly (LLY) rose 1.31% this week to close at $1,273.46, while the S&P 500 fell 0.47%, leaving the stock about 1.78 percentage points ahead of the benchmark. The weekly range was 6.6%, with an up-and-down pattern: Monday opened at $1,243.39 and slipped to a low of $1,239.10; Tuesday gapped higher, hit $1,311.75 intraday, and closed at $1,283.66; Thursday reached a weekly high of $1,321.21; Friday climbed to $1,307.92 before pulling back to end at $1,273.46. Average daily volume of roughly 2.35m shares was in line with the median. ## Key Events Lilly’s week turned on obesity and manufacturing capacity. On Tuesday 20 October, an analysis showed Novo’s CagriSema helped women lose 25% of their weight on average; Lilly rallied intraday and broke above $1,300 to a record high, with attention on oral weight-loss drug Foundayo. The same day brought a correction to an earlier report that Lilly’s Omvoh had hit its goal in a Phase 3 study. On Thursday 22 October, Lilly broke ground in Richmond, Virginia on a $5bn integrated antibody-drug conjugate (ADC) plant, advancing its build-out of 10 new U.S. sites since 2020; the stock rose 3.37% and hit a 52-week high. The company was also set to announce quarterly earnings on Thursday, then fell 3.33% on Friday 23 October. Over the weekend, Lilly presented first clinical data for its next-generation FRα-targeting ADC in platinum-sensitive ovarian cancer at ESMO 2026. ## Analyst Ratings Of 33 institutions covering Lilly, 20 rate it buy, 6 rate it overweight, 3 hold, 1 underweight, 1 sell, and 2 have no opinion; the consensus breakdown also shows 20 strong buy, 3 hold, 1 underweight, and 1 sell. The consensus rating is buy, with a consensus target of $1,331.55, about 4.56% above the latest price of $1,273.46. Targets range from $930 to $1,600, a spread of roughly $670 that points to meaningful disagreement. Lilly ranks first among 203 institutions covering the pharmaceutical sector. ## The Week Ahead The main event is Lilly’s Q3 FY2026 earnings on Thursday 29 October, where estimates point to EPS of about $8.08 and revenue of about $22.6bn. The macro calendar is heavy next week: Dallas Fed manufacturing activity on Monday 26 October, followed on Tuesday 27 October by durable goods orders, FHFA and Case Shiller home prices, new home sales, the Richmond Fed composite, and consumer confidence. In the obesity-drug space, the protein boom paired with tighter consumer scrutiny remains a live theme that could frame demand expectations. ## In Short Lilly’s upward move this week rode obesity-drug momentum and the company’s expansion into ADC capacity, while valuation sits at elevated levels: about 44.88x P/E and 35.38x P/B. The rating backdrop leans positive, but the target spread is wide. The latest session’s fund flow was mixed: large-lot and retail money turned net sellers while medium-lot money turned net buyer. The next test is the 29 October earnings print, and whether it can support the stock’s rich multiple amid a shifting competitive landscape and the pace of capacity rollout. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) ## Related News & Research - [Eli Lilly and Company $LLY Shares Sold by Essential Planning LLC.](https://longbridge.com/en/news/302956671.md) - [Eli Lilly and Company $LLY Shares Sold by USAdvisors Wealth Management LLC](https://longbridge.com/en/news/302964762.md) - [Correction to Eli Lilly's Omvoh Hits Goal in Phase 3 Study Article on Oct. 19](https://longbridge.com/en/news/302438751.md) - [Eli Lilly and Co Stock (LLY) Opened Up by 5.01% on Oct 20: A Full Analysis](https://longbridge.com/en/news/302432875.md) - [METiS TechBio signs $1.1B AI drug-delivery deal with Eli Lilly](https://longbridge.com/en/news/302360581.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**